Edition:
United States

Minerva Neurosciences Inc (NERV.OQ)

NERV.OQ on NASDAQ Stock Exchange Global Market

7.65USD
25 May 2017
Change (% chg)

$0.30 (+4.08%)
Prev Close
$7.35
Open
$7.35
Day's High
$7.72
Day's Low
$7.30
Volume
28,052
Avg. Vol
38,586
52-wk High
$15.83
52-wk Low
$3.45

NERV.OQ

Chart for NERV.OQ

About

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment... (more)

Overall

Beta: --
Market Cap(Mil.): $269.78
Shares Outstanding(Mil.): 36.70
Dividend: --
Yield (%): --

Financials

  NERV.OQ Industry Sector
P/E (TTM): -- 138.86 17.42
EPS (TTM): -0.99 -- --
ROI: -32.12 2.17 -5.45
ROE: -38.96 0.04 -4.73

BRIEF-Minerva provides update on phase 3 design and development strategy for MIN-101

* Minerva provides update on phase 3 design and development strategy for MIN-101

May 15 2017

BRIEF-Minerva Neurosciences announces outcome of meeting with FDA

* Minerva announces outcome of end-of-phase 2 meeting with FDA

May 15 2017

BRIEF-Minerva Neurosciences reports Q1 loss per share $0.30

* Minerva Neurosciences reports first quarter 2017 financial results and business updates

May 04 2017

BRIEF-Minerva Neurosciences Q1 loss per share $0.30

* Minerva Neurosciences reports first quarter 2017 financial results and business updates

May 04 2017

BRIEF-Minerva Neurosciences reports Q4 loss per share $0.27

* Minerva Neurosciences reports fiscal 2016 fourth quarter and year end financial results and business updates

Mar 13 2017

BRIEF-Minerva Neurosciences reports Q4 loss per share of $0.27

* Minerva Neurosciences reports fiscal 2016 fourth quarter and year end financial results and business updates

Mar 13 2017

More From Around the Web

Earnings vs. Estimates